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ABSTRACT 
Alzheimer's disease affects cognitive function through formation of ß- secretase mediated 
extracellular cerebral protein plaques and intracellular neurofibrillary tangles, thus its 
antagonism could mitigate disease progression. This project aims to identify newly obtained and 
optimized molecules which decrease the formation of ß -amyloid plaques through inhibition of 
the ß- secretase enzyme. Protein databank (PDB) depositions describing the bound coordinates 
of 6 lead structures complexed with ß- secretase were identified (PDB ID- 2VKM, 4B05, 4IVS, 
3U6A, 3IGB, 2Q11) as leads for in silico ligand based and de novo design of novel antagonist 
molecules. For the first part of this study, ligands extracted from the protein were used as 
templates for screening ViCi Hamburg‟s database. Protomols were generated for each of the 
ligands using the Surflex Dock suite in SYBYL-X. The molecules received through ViCi were 
then used as ligand sources. For the second part of the study the ligand binding affinity (LBA) of 
each small molecule for its cognate receptor was calculated in X-Score for baseline affinity 
establishment. 2D topology maps highlighting the important interactions between ligand and 
receptor were generated using Poseview, and noncritical moieties were computationally removed 
in the process of creating seed structures (n=3, 2, 3,2,2,2 respectively) on to which novel 
moieties were computationally introduced using the GROW module of LigBuilder. Protomol and 
Keysite volumes were then compared using UCSF Chimera. 1636 novel structures were 
generated with 253 structures being Lipinski Rule compliant. The highest ranking molecules 
from each pharmacophoric family were identified for optimization and in vitro validation. 
Keywords: Beta- Secretase, BACE1, Alzheimer‟s Disease, de novo drug design, in silico ligand- 
based drug design. 
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INTRODUCTION 
Alzheimer‟s Disease (AD) is the most common form of dementia, where the brain is physically 
damaged, affecting an individual‟s daily activities, which relate to memory, thinking and 
behavior. As defined by the Alzheimer‟s Association, AD is a degenerative disease; which 
means that gradually, more parts of the brain become damaged. As this happens, the symptoms 
become more severe 
1
.  
AD was first described by the German neurologist Alois Alzheimer, as a physical disease which 
affects the brain. As the disease progresses, extracellular protein plaques (amyloid-beta proteins) 
and intracellular neurofibrillary tangles (microtubule associated tao proteins) develop in different 
parts of the brain, leading to the death of brain cells. People with Alzheimer's also have a 
shortage of some important chemicals, which are important for the transmission of messages 
within the brain. Persons with AD may experience various symptoms. The symptoms of AD and 
allied regression do not manifest uniformly amongst patients, however there are recognized 
general stages, based on a system developed by Reisberg, which divides the progress of the 
disease symptoms into 7 stages 
2
. 
There is still no recognized curative treatment or medication for curing AD, however the 
symptoms including memory loss, anxiety, behavioral changes; may be controlled by some 
drugs. The most frequently used drugs are cholinesterase inhibitors. As the name implies, they 
inhibit the breakdown of acetylcholine, a neurotransmitter important for electric transmission in 
neurons, thus reducing memory degeneration.  
 “It is generally recognized that an excess level of amyloid- Beta (Aβ) in the brain over a long 
time period is a leading factor in the pathogenesis of Alzheimer‟s Disease (AD)” (Selkoe and 
Schenk, 2008) 
3
.  
β-Secretase, also known as BACE1, is a transmembrane aspartic protease that makes specific 
cleavages during the maturation of some protein chains. These types of proteins are known as 
trimming proteins. The enzyme is normally found in the endoplasmic reticulum and in Golgi 
Bodies, where it trims proteins important to neuronal function. These include the protein 
neuregulin, which helps in the control of the formation of myelin sheaths around nerve axons, 
and voltage-gated sodium channels, which are important for the transmission of nerve signals. 
The BACE1 is structurally similar to the digestive protease pepsin. They both have a deep active 
site cleft which grips the protein chains, and a pair of aspartate amino acids which make the cut. 
The difference between the two is that BACE1 has a long tail that attaches it to the membrane 
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surface, so that the enzyme cannot float freely around the cell, causing cleavage of other 
important proteins which should not be cleaved 
4
. 
BACE1, however, also makes a specific cut in the amyloid-beta precursor protein (APP), 
breaking the protein chain and releasing a large portion of it, which explains why it is also 
known as BACE1- β-site amyloid precursor protein cleaving enzyme 1. A second protease 
known as γ-secretase then cleaves the other side of the protein, and a small, dangerous peptide, 
known as the amyloid- β, is subsequently formed. In small amounts, this peptide is important for 
synaptic function. However, if BACE1 is overactive, this peptide builds up and can combine into 
tangled fibers. If these fibers form in nerve cells, they can block nerve transmission which leads 
to AD. This is the reason why BACE1 is currently recognized as one of the major targets for the 
management of AD.  
The BACE1 active site is located within the extracellular domain of the protein. Its active site is 
made up of two aspartate residues- Asp
32
 and Asp
228
 hence its classification as an aspartic 
protease (Figure 1). This is due to its nature as an aspartyl protease. The R groups of both 
aspartates coordinate a single water molecule between the two, allowing for a nucleophilic attack 
to occur at the carbonyl groups 
4
. 
This project consequently aims to identify newly obtained and optimized molecules, which 
inhibit, or decrease the formation of the β- amyloid plaques through inhibition of the BACE1, 
with potential for clinical use in the therapeutic management of AD. 
 
Figure 1: The two aspartyl residues Asp32 and Asp228, present in the active site of BACE1, 
based on the co-ordinates of PDB ID 2VKM (Ghosh et al, 2008), rendered in Chimera 
(Pettersen EF et al, 2004) 
21
. 
MATERIALS AND METHOD 
Six X-ray crystallographic depositions describing the bound co-ordinates of six ligands with 
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BACE1 were selected from the Protein Data Bank (PDB) 
5
. 
These were PDB ID 2VKM describing the holo- BACE1 bound to its cognate ligand GRL-8234 
(Ghosh et al, 2008) 
6
, PDB ID 4B05, describing the bound co- ordinates of the holo- BACE1 to 
the experimental drug AZD3839 (Jeppsson et al, 2012) 
7
 and PDB ID 4IVS, describing the holo- 
BACE1 to the indole acylguanidine inhibitor (Zou et al, 2013) 
8
, PDB ID 3U6A describing the 
holo- BACE1 bound to an aminopiperazinone ligand (Tresadern et al, 2011) 
9
, PDB ID 3IGB 
describing the holo- BACE1 bound to an aminoimidazole ligand (Malamas et al, 2009) 
10
, and 
PDB ID 2Q11 describing the holo- BACE1 bound to an aminoquinazoline (Baxter et al, 2007) 
11
. Each deposition was visualized and edited in SYBYL
®
- X 1.2
12
 molecular modeling software, 
prior to Ligand Binding Affinity (LBA) estimation. Water molecules at a distance ≥ 5 Å from the 
BACE1_LBP were deleted. At the end of the process a file saved in .mol2 format containing the 
bound co-ordinates of the extracted small molecules and another file saved in .pdb format 
containing the apo receptor, without the deleted water molecules were generated.  
Part 1 – in silico ligand- based drug design 
The online freeware, ViCi 
13
 was used for screening the extracted ligands, GRL_8234.mol2, 
AZD3839.mol2, ACYLGUAN.mol2, 18P.mol2, CMPND3.mol2, Structure1.mol2 from PDB 
crystallographic depositions 2VKM, 4B05, 4IVS, 3U6A, 3IGB, and 2Q11 
6-11
 respectively. The 
six .mol2 files were converted to .pdb format using SYBYL®- X 1.2 
12
. They were subsequently 
used as templates for the ViCi 
13
 screening process. 
A protomol was generated using SYBYL
®
- X 1.2 
12
 for each of the six ligands. The six original 
PDB files 2VKM, 4B05, 4IVS, 3U6A, 3IGB and 2Q11 
6-11
 were retrieved from the RCSB server 
through SYBYL
®
- X 1.2 
12
. The process described below was therefore performed for each of 
the six PDB depositions.  
The ligand was extracted from the protein backbone, while the water molecules together with 
any other ions deemed inessential for ligand stability were removed from the protein. To 
generate the protomol, the area occupied by the ligand (the active site) was used as placement for 
the Surflex-Dock process.  
The molecules that were identified from the molecular database ViCi 
13
 during the virtual 
screening process in .pdb format, were converged into a single .sdf format file using Mona 
(Hilbig and Rarey, 2015) 
14
. 7 Lipinski Rule compliant decoy molecules were chosen arbitrarily 
and added to the others in the same .sdf file. Ligand filtering was performed in Mona 
14
, in order 
to ensure that only Lipinski Rule compliant ligands would be considered further. These were 
saved as a single .sdf file. This process was performed for each of the six ligands, resulting in 
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five .sdf files, namely containing Lipinski Rule compliant molecules with potential to act as 
ligands in the protomol owing to the fact that one of the six template molecules produced a 
cohort of molecular structures that were all Lipinski Rule non-compliant. 
Each of the .sdf files prepared were chosen separately as Ligand Sources, and the Surflex Dock 
process was run for each PDB crystallographic deposition, except 2VKM 
6
, which resulted in no 
Lipinski Rule compliant molecules. 
Part 2 - de novo drug design  
In this step the extracted ligand molecules in .mol2 format and their respective protein binding 
pocket .pdb files, from part 1, were transferred to X-Score
®
 v1.3 (Wang et al, 1998) 
15
, which 
runs on a Linux Platform. The X-Score
®
 v1.3
15
 algorithm was used to quantify (pKd) the LBA of 
each ligand for its cognate receptor. This process was done to establish a baseline affinity against 
which the LBAs of other seeds would then be compared. 
A thorough study of the structure activity relationship for PDB depositions 2VKM, 4B05, 4IVS, 
3U6A, 3IGB, and 2Q11 
6-11
 was carried out. Important moieties listed in each of the six ligands‟ 
published articles were retained. Secondly PoseView v1.1.2 
16
 was used in order to facilitate 
SAR understanding by generating 2D topology maps. All bonds and interactions marked as 
critical to binding by PoseView
 
v1.1.2 
16
 were taken into consideration when creating seeds so as 
to try not disrupt the moieties essential to binding. Thus, moieties which were deemed not 
important for binding, were selected as sites for molecular growth, while moieties deemed 
important to ligand stability and affinity were retained as much as possible. Seed structures were 
then created for each of the six resident ligands, based on the acquired SAR. 
de novo design was carried out using LigBuilder
® 
v1.2 (Wang et al, 2000) 
17
 suite, which is 
divided into 3 modules namely POCKET, GROW and PROCESS. The POCKET module, 
identifies pharmacophoric structural features and key interaction sites that a hypothetical ligand 
for a given Ligand Binding Pocket (LBP) could occupy. In this study, the PDB version of the 
apo- BACE1 (Patel et al, 2004) 
18
 was investigated and the bioactive conformation of the six 
ligands selected (saved in .mol2 format) served as a probe in order to elucidate the 3-D volume 
of BACE1_LBP and to generate a basic pharmacophoric structure for ligands of this binding 
pocket. In this study, each of the six ligands extracted from the six PDB files in .mol2 format 
were used to probe the cognate receptor in PDB file format according to the POCKET algorithm. 
The resulting data was then used by the GROW module of LigBuilder
® 
v1.2 
17
 through which de 
novo design was actually performed. The next process of the study utilized the GROW module 
of LigBuilder
®
 v1.2 
17
. This module has the ability to construct ligand molecules for a target 
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protein in this case BACE1, by applying the inbuilt growing strategy algorithm. This growing 
strategy is contingent on the provision of appropriate seed structures. In this step of the study the 
seeds were allowed to grow alternative side chains. Each of the designed seed structures saved in 
mol2 format were transferred to LigBuilder
® 
v1.2 
17
 for use in the GROW phase of the de novo 
design study. Each of the 14 seeds were made up of only one fragment, therefore the GROW 
strategy was used to guide unidirectional molecular growth.  
An assessment to predict the drug-likeness for the de novo ligands was carried out based on the 
parameters of Lipinski‟s Rule of 5 (Lipinski et al, 2001) 19 by transferring each individual de 
novo ligand to Discovery Studio v4.0, which determined the compliance of such de novo ligands 
to Lipinski‟s Rule of 5 based on the following parameters:  
Number of Hydrogen bond donors‟ ≤ 5 
Number of Hydrogen bond acceptors ≤ 10  
The compliance of the seeds to the other two parameters, namely   
Molecular weight < 500 
Octanol – water partition coefficient ≤ 5 
was determined by choosing the seeds from each of the index files obtained from LigBuilder
®
 
v1.2 
17
 after performing the GROW strategy as mentioned in the previous section.  
Comparison 
The Protomol and Keysite volumes were calculated and analyzed using SYBYL
®
- X 1.2
12
 by 
loading each protomol and keysite into SYBYL
®
- X 1.2 
12
 consecutively and running the 
„Multiple Volume‟ process for each one.  
RESULTS AND DISCUSSION 
in silico ligand- based drug design results 
A protomol was generated for each of the six chosen PDB crystallographic depositions of the 
BACE1 using SYBYL
®
- X 1.2 
12
 Surflex Dock process- 2VKM, 4B05, 4IVS, 3U6A, 3IGB, and 
2Q11 
6-11
.The number of Lipinski Rule compliant molecules for each PDB file received by ViCi 
13
 are shown in Table 1. The Surflex Dock Process was performed & resulted in a total of 2736 
Lipinski Rule compliant molecules. The top 6 ligands with highest Total Score are shown in 
Table 2.  
Table 1: Lipinski Rule Compliant Molecules for each set of ViCi Results. 
PDB ID 2VKM 4B05 4IVS 3U6A 3IGB 2Q11 
Lipinski Rule Compliant ViCi Ligands 0 357 658 626 487 608 
Total Lipinski Rule Compliant Ligands 0 364 665 633 494 615 
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including 7 decoy molecules 
Table 2: Top 6 ligand molecules with the highest Total Score. 
Ligand 
Source 
Molecule ID 3D structure Total 
Score 
(pKd) 
4B05 Asinex_ASN_05381986 
 
 
7.67 
3U6A 0058_Chemti_LT-
1204_X_0039 
 
7.63 
2Q11 0215_Amri_ALB-
H00728600 
 
7.61 
4B05 Chembridge_11204462 
 
7.53 
2Q11 0716_Chemti_NPP1152 
 
7.45 
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4B05 Amri_ALB-H00452300 
 
7.39 
de novo drug design results 
Table 3 depicts the LBA (pKd) of the six ligands GRL-8234 (PDB ID 2VKM) 
6
, AZD3839 
(PDB ID 4B05) 
7
, the indole acylguanidine (PDB ID 4IVS) 
8
, the aminopiperazinone (PDB ID 
3U6A)
9
, the aminoimidazole (PDB ID 3IGB) 
10
, and the aminoquinazoline (PDB ID 2Q11) 
11
. 
These baseline affinities were obtained using X-Score
®
 v1.3 
15
 by loading apo- BACE1 
18
 in .pdb 
format and docking the ligands in .mol2 format in the BACE1_LBP. 
Table Error! No text of specified style in document.: Predicted in silico LBA (pKd) of the six 
template ligands for BACE1. 
Ligand in silico LBA (pKd) 
GRL-8234 (PDB ID: 2VKM) 8.86 
AZD3839 (PDB ID: 4B05) 7.07 
Indole Acylguanidine (PDB ID: 4IVS) 6.16 
Aminopiperazinone (PDB ID: 3U6A) 6.38 
Aminoimidazole (PDB ID: 3IGB) 5.98 
Aminoquinazoline (PDB ID: 2Q11) 6.76 
Ligand Generation- 
Seed structures were created for each of the six ligands as follows- 
- 3 seed structures created from PDB ID 2VKM (6) ligand GRL-8234 
- 2 seed structures created from PDB ID 4B05 (7) ligand AZD3839 
- 3 seed structures created from PDB ID 4IVS (8) indole acylguanidine ligand 
- 2 seed structures created from PDB ID 3U6A (9) aminopiperazinone ligand 
- 2 seed structures created from PDB ID 3IGB (10) aminoimidazole ligand 
- 2 seed structures created from PDB ID 2Q11 (11) aminoquinazoline ligand 
Table 4 shows the number of molecules and their respective families generated from the 
respective seed structure. 
Table 4: Number of novel structures generated from each seed. 
PDB ID Seed Number Number of Families Number of Molecules Highest pKd 
2VKM 1 1 1 5.28 
 2 1 2 5.95 
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 3 5 8 5.98 
4B05 1 1 1 5.18 
 2 6 14 5.97 
4IVS 1 18 200 9.76 
 2 23 200 9.88 
 3 4 10 6.35 
3U6A 1 12 200 8.87 
 2 21 200 6.72 
3IGB 1 8 200 9.95 
 2 9 200 8.35 
2Q11 1 14 200 9.99 
 2 8 200 10.00 
Top Lipinski Rule compliant de novo ligands with a higher LBA than the template ligand, for 
each seed structure are represented in Table 5. 
Table 5: Table showing the top Lipinski Rule compliant ligands with a higher LBA than 
the template ligand, for each seed structure. 
Ligand 
Source 
Seed 
Number 
Molecule 
ID 
Molecular Structure Ligand Binding 
Affinity (pKd) 
2VKM 1 / / / 
 2 / / / 
 3 / / / 
4B05 1 / / / 
 2 / / / 
4IVS 1 Result 72 
 
7.72 
 2 / / / 
3U6A 1 Result 147 
 
7.67 
 2 Result 1 
 
6.8 
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3IGB 1 Result 160 
 
8.75 
 2 Result 143 
 
7.32 
2Q11 1 Result 121 
 
9.27 
 2 Result 133 
 
9.9 
Protomol volumes and Keysite volumes calculated in SYBYL
®
- X 1.2 (12) are shown in Table 6. 
The volumes were calculated using SYBYL
®
- X 1.2 (12). 
Table 6: Comparison of key site and protomol volumes (Å³). 
PDB Deposition Key site Volume (Å
3
)  Protomol Volume (Å
3
) 
2VKM 905 1538 
4B05 683 897 
4IVS 858 1244 
3U6A 179 914 
3IGB 257 572 
2Q11 385 1013 
DISCUSSION 
de novo design may be defined as the design of lead compounds by adding moieties to a 
molecule, within a model of the target receptor or active site, the structure of which is already 
known. This approach thus attempted to identify novel inhibitors for the BACE1 active site that 
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were also Lipinski Rule compliant. Seed structures were created for each PDB crystallographic 
deposition selected with the aim to grow ligands with even higher affinities than the original lead 
compounds.  
The three seed structures created from GRL-8234 
6
 resulted in a total of 7 families. Since none of 
the molecules were Lipinski Rule compliant and none had a higher LBA than the original ligand 
they were deemed not important for further optimization. For seed 1 LigBuilder
® 
v1.2 
17
 added a 
methyl (-CH3) moiety to the growing site, causing Result 1 to have a lower affinity than the 
original GRL-8234 ligand 
6
 so adding this moiety was deemed to decrease the LBA. For seed 2, 
Result_001 had a lower logP and the higher LBA from the two resulting molecules, making it 
the better result generated from this seed. The addition of 2 methyl moieties in each molecule 
resulted in two different binding affinities so this was deemed to be caused by the different 
spatial placement of the added moieties. Seed 3 generated 5 families with a total of 8 molecules, 
with Result 1 from Family 1 being the best and Result 7 from Family 4 being the worst in LBA, 
hence the pharmacophore for family 1 was deemed to contribute to a greater LBA than that of 
Family 4.  
The two seed structures created from AZD3839 
7
 resulted in a total of 7 families containing 15 
molecules in all. The two Lipinski Rule compliant molecules obtained, both from seed 2, one 
from family 1, and the other from family 3 unfortunately had a lower LBA than the original 
binding affinity for ligand AZD3839 so they were also deemed not satisfactory for further 
optimization. 
The moiety grown in LigBuilder
® 
v1.2 
17
 for seed 1, Result 1, contributed to a lower LBA. For 
seed 2, the two Lipinski Rule compliant molecules generated, had a logP between 3 and 5, which 
is within parameters for Lipinski Rule of Five compliancy, however, with a LBA of 5.61 (Result 
1) and 5.38 (Result 8) they both had lower LBA than the original ligand AZD3839 
7
.  
The three seed structures created from indole acylguanidine 
8
 resulted in a total of 410 molecules 
generated using LigBuilder
® 
v1.2
17
. The two Lipinski Rule compliant molecules obtained were 
from seed 1, family 2, and the other from seed 3, family 9. The LBA of the ligand from seed 1, 
family 2 (Result 72) was both Lipinski Rule compliant and also had a higher LBA (pKd = 7.72) 
than the original molecule (pKd = 6.16) so the moiety grown by LigBuilder
® 
v1.2 (17) was seen 
to contribute to an increased LBA and thus deemed to be a valid candidate for further 
optimisation. LogP was 4.93, which is within the parameters set by Lipinski‟ s Rule of Five 19, so 
all calculated values were within the parameters for a CNS acting drug (Ghose et al, 2012) 
20
 
with high affinity for BACE1. Result 1 from Family 1 had the highest LBA of 9.76 however was 
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not Lipinski Rule compliant, while Result 46 had the lowest LBA of 7.71 from Family 1 and was 
also not Lipinski Rule compliant.  
200 novel structures were generated from each seed of the aminopiperazinone, aminoimidazole 
and aminoquinazoline class.  
The first aminopiperazinone seed yielded molecules from 6 different families. The second 
aminopiperazinone seed yielded molecules from 12 different families. The families differed from 
one another by having a different pharmacophoric scaffold. 27.5% of the novel molecules 
generated from the aminopiperazinone seeds were found to be Lipinski rule compliant 
19
. 
Seed 1 from the aminoimidazole class yielded novel structures from 6 different families. The 
second aminoimidazole seed generated molecules from 9 different families. Compared to the 
structures generated from the other 2 classes considered, the novel molecules yielded from the 
aminoimidazole seeds showed a sharp increase in Lipinski rule compliance, with 88% of the 
total generated structures being compliant. 
The first seed from the aminoquinazoline class yielded molecules from 6 different families 
whilst the second aminoquinazoline seed yielded molecules from 4 different families. Only 7.5% 
of the total novel aminoquinzoline-derived structures were found to be Lipinski compliant. 
The in silico ligand- based drug design method resulted in discovering new molecules, which 
were previously not studied in the BACE1 active site. A number of Lipinski Rule compliant 
molecules gave a Total Score of 6 or higher. This part of the study may also be considered to 
take a more innovative approach than the de novo process due to the larger surface area and 
volume explored through the creation of the protomol. As can be seen in the results section, the 
protomols created by SYBYL
®
- X 1.2
 12
 all had a larger surface area and volume than the LBP 
map created by LigBuilder
® 
v1.2 
17
. This allowed for more robust exploration of the active site, 
thus providing more possible interaction sites than the LBP map generated by LigBuilder
® 
v1.2 
17
. 
Analysis of the top six structures shed light on important properties.  
Molecule Asinex_ASN_05381986, which exhibited the highest Total Score interacts with the 
active site through many different favorable interactions. The only unsatisfied moieties are the 
nitrogen atoms in the tetrazolidine moiety.  
0058_Chemti_LT-1204_X_0039, which exhibited a Total Score of 7.63 and also interacts with 
the BACE1 active site through many favorable interactions. The unsatisfied moieties are two 
oxygen atoms. 
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0215_Amri_ALB-H00728600 exhibited a Total Score of 7.61 and also interacts with the BACE1 
active site through many favorable interactions. The unsatisfied moieties are two hydrogen atoms 
and an oxygen atom. 
Chembridge_11204462, which exhibited a Total Score of 7.53 also interacts with the BACE1 
active site through many favorable interactions. The unsatisfied moieties are mainly nitrogen and 
oxygen atoms. 
0716_Chemti_NPP1152, which exhibited a Total Score of 7.45 interacts with the BACE1 active 
site through many favorable interactions. The unsatisfied moieties are mainly nitrogen, oxygen 
and hydrogen atoms. 
Amri_ALB-H00452300 exhibited a Total Score of 7.39 and also interacts with the BACE1 
active site through many favorable interactions. The unsatisfied moieties are three oxygen atoms. 
Limitations 
As with any in silico drug design study, the project was conducted using a static, rigid LBP, 
which is different from in vivo modeling and may thus yield different results. This was a 
limitation of the freeware used and of SYBYL
®
- X 1.2
 
(12) which could not be overcome.  
CONCLUSION 
In further studies the primary recommendation would be to optimize further the top ranking 
molecules from both cohorts, and also to then allow both enzyme and ligand to adopt 
complementary conformations to each other upon binding. Although a time consuming process, 
invaluable information can be achieved. The yielded results would then pave the way for further 
molecular dynamic evaluation and in vitro assay together with further necessary structural 
optimization. 
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